SAB Biotherapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from SAB Biotherapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 845% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 89% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-71.0×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 78% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-47.1×Operating cash was negative last year, while some debt falls due within a year.
Lower than 72% of Healthcare companies in United States.
Cash Cushion Ratio
+33%Cash, after subtracting all debt, equals 33% of its market value (net cash).
Higher than 70% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
SAB Biotherapeutics, Inc. made a loss over the last year. SAB Biotherapeutics, Inc. owes $0.10 for every $1 it owns. SAB Biotherapeutics, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossSAB Biotherapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.29The share price is 1.29 times SAB Biotherapeutics, Inc.'s book value per share, lower than 73% of Healthcare companies in United States.
Market cap
$277 MThe total market value of all of SAB Biotherapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 53% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$215 MWhat SAB Biotherapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.36Net worth divided by the number of shares. The share price of $3.04 is 1.3 times this, which is the P/B above.
Return on equity (ROE)
-11.3%SAB Biotherapeutics, Inc. lost 11.3% of its shareholders' money over the last year, higher than 70% of Healthcare companies in United States.
Owes vs Owns
0.10×SAB Biotherapeutics, Inc. owes $0.10 for every $1 it owns (low), lower than 87% of Healthcare companies in United States.
Dividend yield
NoneSAB Biotherapeutics, Inc. does not currently pay a dividend.
Profit growth
Back to profitSAB Biotherapeutics, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Cash quality
-3.4×Cash from SAB Biotherapeutics, Inc.'s business was -3.4× its reported profit in the year to Dec 2025 — the business used cash even though it reported a profit.
Interest cover
Not coveredSAB Biotherapeutics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashSAB Biotherapeutics, Inc. held $91 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For SAB Biotherapeutics, Inc.: $277 M ÷ $215 M (30 Jun 2026) = 1.3.
What is SAB Biotherapeutics, Inc.'s return on equity?
SAB Biotherapeutics, Inc. lost 11.3% of its shareholders' money over the last year, higher than 70% of Healthcare companies in United States.
How much does SAB Biotherapeutics, Inc. owe compared with what it owns?
SAB Biotherapeutics, Inc. owes $0.10 for every $1 it owns (low), lower than 87% of Healthcare companies in United States.
Does SAB Biotherapeutics, Inc. pay a dividend?
No. SAB Biotherapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.